T reatment recommendations for men with localized prostate cancer (PC) are based on risk stratification. 1 Men with low-risk PC who have a life expectancy of at least 10 years may be offered radical prostatectomy (RP), externalbeam radiotherapy (EBRT), brachytherapy, or active surveillance (AS) as an initial treatment. Active surveillance involves monitoring the course of PC with the expectation to initiate curative treatment if the cancer progresses.
1,2 Follow-up of AS consists of annual transrectal ultrasonographically guided needle biopsies of at least 12 cores, semiannual prostate-specific antigen (PSA) measurements, and annual digital rectal examinations (DREs). Progression on surveillance can include any of the following: Gleason grade 4 or 5 PC found on repeat biopsy; PC found in a greater number biopsy cores or occupying a greater amount of the prostate biopsy cores; or a new nodule felt on DRE. In earlier experience with AS, PSA kinetics were used as a marker of disease progression; however, the clinical utility of PSA measurement for predicting progression has since been questioned 3 : a rapid rise in PSA alone is no longer considered a reason to initiate curative treatment. Given the data from the Prostate Cancer Intervention vs Observation Trial (PIVOT) 4 suggesting a lack of benefit in men with low-risk PC when managed with RP vs watchful waiting, AS has become the preferred option for these men. While men in the PIVOT study were considered less healthy than men in the Surveillance, Epidemiology and End Results (SEER)-Medicare population, 5 the results suggested that men with lowrisk PC might not be at an increased risk of death from PC during the first decade after diagnosis if actively monitored.
6
The intermediate-risk group is heterogeneous with respect to the risk of PSA recurrence and PC-specific mortality (PCSM) following treatment with RP, EBRT, or brachytherapy. Therefore, Zumsteg and colleagues 6 divided inter- 
Methods
This study was performed with the approval of the independent institutional review board IntegReview, which is fully accredited by the Association for the Accreditation of Human Research Protection Programs. Each participant provided written informed consent at the time of initial consultation, allowing his deidentified clinical and PC-related information to be collected and entered into a secure, password-protected database for subsequent outcomes analysis.
Patient Population and Treatment
We studied a prospective cohort of 5580 men 
Follow-up and Determination of Cause of Death
The primary end point of the study was the risk of PCSM. The risk of ACM was a secondary end point. Follow-up began on the date of prostate brachytherapy after the completion of treatment and continued to the date of death or the date of last data set update, June 1, 2013, whichever was earlier. Follow-up involved serial PSA measurements followed by a DRE every 3 months for 2 years, every 6 months for an additional 3 years, and then annually thereafter. To be classified as having died of PC, men had to have radiographic documentation of metastatic PC and a rising PSA despite salvage ADT and in most men cytotoxic chemotherapy. Patient age and year of treatment were included because both increasing age 23, 24 and earlier year of treatment 25 have previously been shown to be associated with increased risk of PCSM. Given that a protopathic bias may exist when treatment is inadvertently initiated before diagnosis (or in the current study, before AS) and that all men in the current study were treated, we performed sensitivity analyses using left truncation durations of 6, 9, and 12 months to see whether our results would differ. 26 Adjusted Estimates of PCSM and ACM Cumulative incidence estimates [27] [28] [29] of PCSM and 1 -Kaplan
Statistical Analysis
Meier estimates of overall survival or ACM were calculated and adjusted for patient age at brachytherapy and year of treatment (given that these factors were significant on the multivariable analysis). That said, the data in the current study were prospectively collected; the sample size is large; and the median follow-up approaches 8 years. Therefore, given only a 0.15% absolute increase of PCSM at 8 years for treated men with for men with favorable intermediate-risk PC and 0.44% for men with low-risk PC in the present study. Fourth, a probable reason for increasing age being significantly associated with an increased risk of PCSM in the adjusted competing risks regression analysis is the known association of increasing age and high-grade PC. 23, 24 Given the sampling error that is associated with prostate biopsies and that older men tend to have larger prostates than younger men secondary to benign prostatic hyperplasia, older men are more likely than younger men to experience undergrading due to increased biopsy sampling error. Therefore, further workup to rule out clinically occult high-grade PC with multiparametric magnetic resonance imaging could be considered before managing PC in older men (age >65 years) with AS (NCT01858688). Finally, given that our study only had a power of 75% to detect a significant difference in the risk of PCSM when comparing men with favorable intermediate-risk PC with those who had low-risk PC, there is a 25% chance that a difference exists that we did not observe or that a type 2 error occurred. 
Conclusions

